NASDAQ:LFCR Lifecore Biomedical (LFCR) Stock Forecast, Price & News $7.58 -0.34 (-4.29%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$7.53▼$8.0050-Day Range$7.47▼$10.8452-Week Range$1.52▼$11.45Volume225,254 shsAverage Volume579,380 shsMarket Capitalization$229.83 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Lifecore Biomedical MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside25.3% Upside$9.50 Price TargetShort InterestBearish6.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.14Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.06) to $0.58 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector708th out of 976 stocksPharmaceutical Preparations Industry332nd out of 456 stocks 3.3 Analyst's Opinion Consensus RatingLifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Lifecore Biomedical has a forecasted upside of 25.3% from its current price of $7.58.Amount of Analyst CoverageLifecore Biomedical has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.77% of the float of Lifecore Biomedical has been sold short.Short Interest Ratio / Days to CoverLifecore Biomedical has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Lifecore Biomedical has recently increased by 11.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLifecore Biomedical does not currently pay a dividend.Dividend GrowthLifecore Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LFCR. Previous Next 2.9 News and Social Media Coverage News SentimentLifecore Biomedical has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lifecore Biomedical this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders14.61% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.85% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.06) to $0.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lifecore Biomedical is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lifecore Biomedical is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLifecore Biomedical has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lifecore Biomedical (NASDAQ:LFCR) StockLifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is based in Chaska, Minnesota.Read More LFCR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LFCR Stock News HeadlinesSeptember 21, 2023 | fool.comLifecore Biomedical (NASDAQ: LFCR)September 5, 2023 | msn.comLifecore Biomedical: Quality CDMO, Potential SaleSeptember 27, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 1, 2023 | finance.yahoo.comLifecore Biomedical, Inc. (NASDAQ:LFCR) Q4 2023 Earnings Call TranscriptSeptember 1, 2023 | finance.yahoo.comQ4 2023 Lifecore Biomedical Inc Earnings CallAugust 31, 2023 | finanznachrichten.deLifecore Biomedical, Inc.: Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 ResultsAugust 31, 2023 | sfgate.comLifecore Biomedical: Fiscal Q4 Earnings SnapshotAugust 31, 2023 | finance.yahoo.comLifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 ResultsSeptember 27, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 31, 2023 | finance.yahoo.comLifecore Biomedical (LFCR) Reports Q4 Loss, Tops Revenue EstimatesAugust 22, 2023 | msn.comLifecore Biomedical gets Nasdaq noncompliance noticeAugust 22, 2023 | finance.yahoo.comLifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual ReportAugust 22, 2023 | finance.yahoo.comLifecore Biomedical Sets Fourth Quarter 2023 Earnings Conference Call for August 31, 2023 at 7:30 a.m. CTAugust 18, 2023 | finance.yahoo.comNew York Times and OneSpan Stock See Action From Activist InvestorsAugust 17, 2023 | finance.yahoo.comImmatics (IMTX) Reports Q2 Loss, Tops Revenue EstimatesAugust 16, 2023 | finance.yahoo.comCove Street Capital, LLC Reduces Stake in Lifecore Biomedical IncAugust 12, 2023 | msn.comGreenhaven Road Capital - Lifecore Biomedical: Gem Of A CDMO BusinessAugust 12, 2023 | finance.yahoo.comDo You Think Lifecore Biomedical (LFCR) Will Get Sold for a Healthy Premium?July 31, 2023 | finance.yahoo.comLifecore Biomedical (LFCR) Does Not Face Bankruptcy Risk NowJuly 22, 2023 | finance.yahoo.comLifecore Biomedical (NASDAQ:LFCR) investors are sitting on a loss of 26% if they invested five years agoJune 29, 2023 | finance.yahoo.comInstitutional investors own a significant stake of 43% in Lifecore Biomedical, Inc. (NASDAQ:LFCR)June 27, 2023 | msn.comLifecore: Highly Skewed Special SituationJune 8, 2023 | finance.yahoo.comWhat Makes Lifecore Biomedical (LFCR) an Attractive Investment Opportunity?June 5, 2023 | barrons.comLifecore Biomedical Inc.June 3, 2023 | finance.yahoo.comLifecore Biomedical Third Quarter 2023 Earnings: Misses ExpectationsJune 1, 2023 | msn.comRecap: Lifecore Biomedical Q3 EarningsJune 1, 2023 | apnews.comLifecore Biomedical: Fiscal Q3 Earnings SnapshotSee More Headlines Receive LFCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address LFCR Company Calendar Last Earnings8/31/2023Today9/27/2023Next Earnings (Estimated)10/05/2023Fiscal Year End5/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LFCR CUSIPN/A CIK1005286 Webwww.lifecore.com Phone(800) 454-1355Fax650-368-9818Employees689Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$10.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+25.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,190,000.00 Net Margins-71.36% Pretax Margin-59.59% Return on Equity-79.34% Return on Assets-19.09% Debt Debt-to-Equity Ratio3.36 Current Ratio2.35 Quick Ratio1.05 Sales & Book Value Annual Sales$103.27 million Price / Sales2.23 Cash Flow$3.93 per share Price / Cash Flow1.93 Book Value$3.08 per share Price / Book2.46Miscellaneous Outstanding Shares30,320,000Free Float25,892,000Market Cap$229.83 million OptionableOptionable Beta1.13 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. James G. Hall (Age 60)CEO, Pres & Director Comp: $711.57kMr. John D. Morberg (Age 59)Exec. VP & CFO Comp: $443.43kDr. Albert D. Bolles Ph.D. (Age 65)Pres of Curation Foods, Inc. Comp: $688.19kMr. Steve W. LaningaVP of OperationsDr. Kipling Thacker Ph.D. (Age 68)VP & Chief Scientist Mr. Aaron PerlitshDirector of Internal Audit & Chief Compliance OfficerMr. Darren M. HieberSr. VP of Corp. Devel. & PartnershipsMs. Kara MorleySr. VP of HRMs. Jackie Q. KleckerExec. VP & GMMr. Matt AugustsonSr. VP of Information TechnologyMore ExecutivesKey CompetitorsEnanta PharmaceuticalsNASDAQ:ENTAGeneration BioNASDAQ:GBIONuvectis PharmaNASDAQ:NVCTAstria TherapeuticsNASDAQ:ATXSFoghorn TherapeuticsNASDAQ:FHTXView All CompetitorsInstitutional OwnershipBarclays PLCBought 8,965 shares on 9/21/2023Ownership: 0.030%Wolverine Trading LLCBought 24,400 shares on 8/23/2023Ownership: 0.000%Citadel Advisors LLCBought 50,700 shares on 8/15/2023Ownership: 0.000%Goldman Sachs Group Inc.Bought 45,236 shares on 8/15/2023Ownership: 0.149%Y Intercept Hong Kong LtdBought 26,258 shares on 8/15/2023Ownership: 0.087%View All Institutional Transactions LFCR Stock - Frequently Asked Questions Should I buy or sell Lifecore Biomedical stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lifecore Biomedical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LFCR shares. View LFCR analyst ratings or view top-rated stocks. What is Lifecore Biomedical's stock price forecast for 2023? 2 Wall Street analysts have issued 12 month target prices for Lifecore Biomedical's stock. Their LFCR share price forecasts range from $9.00 to $10.00. On average, they predict the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 25.3% from the stock's current price. View analysts price targets for LFCR or view top-rated stocks among Wall Street analysts. How have LFCR shares performed in 2023? Lifecore Biomedical's stock was trading at $6.48 at the beginning of 2023. Since then, LFCR shares have increased by 17.0% and is now trading at $7.58. View the best growth stocks for 2023 here. Are investors shorting Lifecore Biomedical? Lifecore Biomedical saw a increase in short interest in September. As of September 15th, there was short interest totaling 2,010,000 shares, an increase of 11.7% from the August 31st total of 1,800,000 shares. Based on an average daily volume of 266,900 shares, the short-interest ratio is currently 7.5 days. Approximately 6.8% of the shares of the stock are sold short. View Lifecore Biomedical's Short Interest. When is Lifecore Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 5th 2023. View our LFCR earnings forecast. How were Lifecore Biomedical's earnings last quarter? Lifecore Biomedical, Inc. (NASDAQ:LFCR) issued its earnings results on Thursday, August, 31st. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.82. The company earned $31.55 million during the quarter, compared to analyst estimates of $28.99 million. Lifecore Biomedical had a negative trailing twelve-month return on equity of 79.34% and a negative net margin of 71.36%. What is Lifecore Biomedical's stock symbol? Lifecore Biomedical trades on the NASDAQ under the ticker symbol "LFCR." Who are Lifecore Biomedical's major shareholders? Lifecore Biomedical's stock is owned by a number of retail and institutional investors. Top institutional investors include Wynnefield Capital Inc. (16.24%), Cove Street Capital LLC (5.34%), BlackRock Inc. (1.75%), Visionary Wealth Advisors (1.65%), Geode Capital Management LLC (0.95%) and Royal Bank of Canada (0.48%). How do I buy shares of Lifecore Biomedical? Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lifecore Biomedical's stock price today? One share of LFCR stock can currently be purchased for approximately $7.58. How much money does Lifecore Biomedical make? Lifecore Biomedical (NASDAQ:LFCR) has a market capitalization of $229.83 million and generates $103.27 million in revenue each year. The company earns $-102,190,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. How many employees does Lifecore Biomedical have? The company employs 689 workers across the globe. How can I contact Lifecore Biomedical? Lifecore Biomedical's mailing address is 2811 AIRPARK DRIVE, SANTA MARIA CA, 93455. The official website for the company is www.lifecore.com. The company can be reached via phone at (800) 454-1355, via email at jeff.sonnek@icrinc.com, or via fax at 650-368-9818. This page (NASDAQ:LFCR) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.